Physician profile
Anna Koziol
NPI 1851787733
$802.82
in general payments reported to CMS, 2019-2025
13 companies · $388 in 2025
The $388 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.55 · 2022: $63.61 · 2023: $51.46 · 2024: $284 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $723.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $191.25 | 2024 | Lifevest |
| Kestra Medical Technology Services, INC. | $176.44 | 2025 | Assure Wcd |
| Novartis Pharmaceuticals Corporation | $173.83 | 2022-2025 | |
| Abbott Laboratories | $56.98 | 2021-2023 | Cardiomems |
| Cvrx, INC. | $32.14 | 2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $31.86 | 2024 | Verquvo |
| Bridgebio Pharma, INC. | $26.50 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $22.14 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.91 | 2024 | Jardiance |
| Radius Health, INC. | $20.42 | 2025 | Tymlos |
| Lilly USA, LLC | $19.29 | 2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $15.59 | 2024 | Farxiga |
| Esperion Therapeutics, INC. | $14.47 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Koziol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.